Polyrizon’s naloxone hydrogel shows positive permeation kinetics

Polyrizon (PLRZ) announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating “promising” permeation kinetics that complement the company’s previously reported stability and mucoadhesion. Following the positive mucoadhesion findings-where Polyrizon’s formulation showed significantly enhanced persistence on ex-vivo nasal tissue compared to a marketed intranasal naloxone product -, the company has completed a series of permeation studies using a validated artificial membrane system. These studies assessed the rate and extent of naloxone diffusion from Polyrizon’s hydrogel in comparison with the commercially available reference product under controlled conditions. Permeation profiles remained rapid, with no statistically significant differences in permeation kinetics when compared to the marketed naloxone product. Stability studies demonstrating robustness of the formulation. These findings reinforce the potential of Polyrizon’s Trap & Target technology to deliver an innovative intranasal naloxone product that combines enhanced mucosal residence time with the essential fast-onset pharmacokinetic behavior expected in real-world emergency scenarios.